<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Clonidine, xylazine, and related imidazoline poisoning
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Clonidine, xylazine, and related imidazoline poisoning
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Clonidine, xylazine, and related imidazoline poisoning
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George Sam Wang, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Wiley, II, MD, MPH
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical features, evaluation, and management of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and related imidazoline intoxication will be reviewed here. The clinical approach to the poisoned patient is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         , an alpha-2 adrenergic agonist, is a biochemical derivative of imidazoline that was initially introduced as a topical nasal decongestant over 40 years ago [
         <a href="#rid1">
          1
         </a>
         ]. Subsequently, clonidine has been primarily utilized for its potent antihypertensive effect but is also administered for a wide variety of indications. Clonidine poisoning may occur from exploratory ingestion by young children (most common mechanism), transdermal exposure from a clonidine patch, malicious drug administration, intentional ingestion, or therapeutic error. Clonidine exposure is frequently symptomatic in children, and pediatric clonidine poisoning is frequently complicated by coma and respiratory depression; fortunately, deaths due to pediatric exploratory ingestion of clonidine are rare [
         <a href="#rid2">
          2-6
         </a>
         ].
        </p>
        <p>
         In the United States, more than 10,000 calls regarding
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         exposure are made annually to regional poison control centers, and serious clinical findings often requiring hospitalization are common [
         <a href="#rid7">
          7,8
         </a>
         ]. As an example, among about 28,000 unintentional clonidine exposures in United States children reported to poison control centers over 11 years, approximately 20 percent had moderate or major clinical effects [
         <a href="#rid2">
          2
         </a>
         ]. In Australia, calls to its largest poison center pertaining to clonidine among children under age 6 years rose steadily each year between 2006 and 2016 and correlated with increased dispensing of clonidine by pediatricians [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Exposures and poisoning caused by imidazoline chemically related to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         are less frequent.
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          Guanfacine
         </a>
         , and the anti-spasticity agent
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         , are also oral central alpha-2 adrenergic agonist medications that are being more commonly prescribed. Guanfacine received US Food and Drug Administration approval for the treatment of Attention Deficit Hyperactivity Disorder for children aged 6 years and older in 2009, and a dramatic increase in pediatric cases of guanfacine ingestion were noted by US poison centers between 2009 and 2012 [
         <a href="#rid9">
          9
         </a>
         ]. Approximately 1500 exploratory guanfacine ingestions by children less than age 6 years are noted by US poison centers annually [
         <a href="#rid2">
          2
         </a>
         ]. Other related imidazolines are found in topical eye and nose decongestants. Adverse events from topical use, and poisoning from oral ingestion, are sporadically reported and can be serious.
        </p>
        <p>
         Xylazine has been found as an adulterant in heroin for decades [
         <a href="#rid10">
          10
         </a>
         ]. It is now commonly found in heroin and illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , often with the street name "Tranq" due to xylazine's reputation as a veterinary tranquilizer [
         <a href="#rid11">
          11,12
         </a>
         ]. In the city of Philadelphia, xylazine was detected in less than 2 percent of fatal opioid overdose cases in 2010 but in 31 percent of such cases in 2019 [
         <a href="#rid13">
          13
         </a>
         ]. Detection of xylazine in illicit opioid samples is spreading across the US [
         <a href="#rid12">
          12,14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PHARMACOLOGY AND CELLULAR TOXICOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H3727322382">
         <span class="h2">
          Imidazoline agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Imidazolines and their common uses include:
        </p>
        <p class="headingAnchor" id="H1381984161">
         <span class="h2">
          Clonidine and other imidazoline medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Common medical uses for
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and other medically approved imidazolines include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         – Clonidine is indicated for the treatment of hypertension in adults, but is also used for adjunctive anesthetic sedation and analgesia, spinal anesthesia, opioid detoxification, alcohol withdrawal, smoking cessation, and amelioration of postmenopausal hot flashes [
         <a href="#rid15">
          15-20
         </a>
         ]. In children, it is used in the treatment of attention deficit disorder with hyperactivity, refractory conduct disorder, and Tourette syndrome [
         <a href="#rid21">
          21-23
         </a>
         ]. It is often prescribed (off-label) for treating sleep disturbances in children [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Guanfacine
         </strong>
         <strong>
          and
         </strong>
         <strong>
          guanabenz
         </strong>
         –
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          Guanfacine
         </a>
         and guanabenz are central alpha-2 adrenergic agonist medications that are chemically related to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         . Guanfacine is frequently prescribed to treat children with behavioral disorders and less commonly to treat hypertension. It is available in regular-release and extended-release formulations [
         <a href="#rid25">
          25
         </a>
         ]. Guanabenz is less commonly prescribed for hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Topical decongestants and glaucoma medications (eg,
         </strong>
         <strong>
          tetrahydrozoline
         </strong>
         <strong>
          ,
         </strong>
         <strong>
          oxymetazoline
         </strong>
         <strong>
          , and
         </strong>
         <strong>
          brimonidine
         </strong>
         <strong>
          )
         </strong>
         – Imidazoline derivatives, such as
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9856" href="/z/d/drug information/9856.html" rel="external">
          naphazoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">
          oxymetazoline
         </a>
         , and
         <a class="drug drug_general" data-topicid="106757" href="/z/d/drug information/106757.html" rel="external">
          xylometazoline
         </a>
         , are found in topical eye and nose decongestant drops.
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          Brimonidine
         </a>
         and
         <a class="drug drug_general" data-topicid="8863" href="/z/d/drug information/8863.html" rel="external">
          apraclonidine
         </a>
         eye drops are prescribed for treatment of glaucoma. Ingestion or systemic absorption of small amounts of these agents can produce toxicity syndromes strikingly similar to those produced by
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         [
         <a href="#rid26">
          26-29
         </a>
         ]. (See
         <a class="local">
          'Physical examination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tizanidine
         </strong>
         –
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          Tizanidine
         </a>
         is a muscle relaxant used for the treatment of spasticity that has caused poisoning similar to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         [
         <a href="#rid27">
          27,30
         </a>
         ]. (See
         <a class="local">
          'Physical examination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lofexidine
         </strong>
         –
         <a class="drug drug_general" data-topicid="117925" href="/z/d/drug information/117925.html" rel="external">
          Lofexidine
         </a>
         is used as an alternative to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         for opioid detoxification. Toxicity in humans has not been described. (See
         <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">
          "Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder", section on 'Alpha-2 adrenergic agonists'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dexmedetomidine
         </strong>
         –
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          Dexmedetomidine
         </a>
         is an alpha-2 agonist frequently used for sedation. (See
         <a class="medical medical_review" href="/z/d/html/82857.html" rel="external">
          "Pediatric procedural sedation: Pharmacologic agents", section on 'Dexmedetomidine'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1606.html" rel="external">
          "Sedative-analgesia in ventilated adults: Management strategies, agent selection, monitoring, and withdrawal", section on 'Dexmedetomidine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Toxic dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         No minimum toxic dose of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         has been established. A review of low-dose clonidine poisonings among children details eight children who developed some combination of central nervous system (CNS), cardiovascular, or respiratory depression after alleged exposure to just one or two tablets [
         <a href="#rid31">
          31
         </a>
         ]. An autistic child who was taking compounded clonidine developed sedation, bradycardia, and hypotension because of an eightfold compounding error by the pharmacy [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         By contrast, survival has been documented after ingested doses that were 1000-fold of regular daily dosing in both children and adults [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p>
         Topical imidazoles (eg,
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">
          oxymetazoline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          brimonidine
         </a>
         ), though structurally similar to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , are more polar than clonidine and less likely to cross the blood-brain barrier. Still, they have been implicated in pediatric poisoning after ingestion of small amounts of drug or after therapeutic use [
         <a href="#rid26">
          26,29,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Mechanism of action
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacological mechanisms through which
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         lowers blood pressure and causes sedation are complex and derive from action at the central and peripheral alpha-2 adrenergic receptors and imidazoline receptors [
         <a href="#rid36">
          36-39
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         and related imidazolines stimulate central alpha-2 adrenergic receptors and imidazoline receptors that are located primarily in the rostral ventrolateral medulla. This effect leads to decreased sympathetic outflow from the CNS and reduced plasma norepinephrine levels [
         <a href="#rid37">
          37,39
         </a>
         ]. Imidazoline-1 receptors are involved in the hypotensive effects of clonidine [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endothelium-derived nitric oxide (NO) also plays a role in the antihypertensive effects of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Further sedative effects may occur from the stimulation of alpha-2 adrenergic receptors in the locus coeruleus, by augmented release of gamma-aminobutyric acid (GABA), and by interaction with opioid and serotonergic receptor systems [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stimulation of peripheral alpha-2 adrenergic receptors located in peripheral vascular smooth muscle causes vasoconstriction. This action explains the utility of imidazoline compounds as topically applied vasoconstrictors and the early and transient hypertension that is occasionally seen following
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         overdose [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H969485652">
         <span class="h2">
          Xylazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xylazine is an alpha-2 agonist used in veterinary medicine for sedation and analgesia. Although it has no approved indications in humans, xylazine has become a drug of abuse and is also found as a common adulterant in heroin and illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , including powder and pill forms [
         <a href="#rid10">
          10,13,14,40-48
         </a>
         ]. The US Food and Drug Administration has issued an alert to health care professionals and a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fnam04.safelinks.protection.outlook.com%2F%3Furl%3Dhttps%253A%252F%252Furldefense.com%252Fv3%252F__https%253A%252Fwww.fda.gov%252Fdrugs%252Fdrug-safety-and-availability%252Ffda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs__%253B%21%21NZvER7FxgEiBAiR_%21okIlIWo8O6yJh5Nep5926oSL4iVfSEHmds6AzDH5atETisOwf8eZTBmLBLr4jokdHHbsz4kAxkyGajrgR_C1jmwOT11IfOKWFfbTX6wC%2524%26data%3D05%7C01%7CLily.Melby%2540wolterskluwer.com%7C77fd0cdcd19c46e7a8f508dad2d5cf20%7C8ac76c91e7f141ffa89c3553b2da2c17%7C0%7C0%7C638054112990584548%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%253D%7C3000%7C%7C%7C%26sdata%3DzgqRq%252FO%252FCExTMg4fmMCjI1nQYopKlJyepC3OSSTCzUU%253D%26reserved%3D0&amp;token=2IcTcKjgCSiQ2gqS%2B3QXIHRzoFEoKTU6GNqmKY1HnNMEOurKICSnzH5nNLf3dTZrx9ybmb4kfJv4xjC%2FdswK8ZIk87o6UWTn0u6Shf3lITdQJxc5a%2B8qIegsQBj%2FjBZnwaKU8hTJ2QgNqfvyKOgehYgasLXTatfZJKJ5I3FFxCA6d4QvvEaOsIYegOOdLlUFuegXy%2BKtO4%2FcxRnP8hZeLJdeL2hyooSqCOsV%2FzQEj7W50phAYcnL32sUsOrUqWuhJMo7AAfLcAuVYzK5LnYh1i7ZmmfrFqRZTXSXBi2g9Zr6CwNAZS%2Brai%2F2Box1JhLvfhZVDOTD%2Bmr5fYE2pcmmcYrq0DBSRANRvHYhBnNCTJw6f2iGdM8OkzhRUd4YyLvXTcb1vbwJWwlvE16WxumnPFaclWXyOdv82LUAFuLScL%2Fjv1WJ3ZPFtXVs0rSGHi3d3jpXOjlhSpxiW7jQMtxPGXWY4z%2B3JoDQ6d8K9BeQr9oxDXQ8vkiSV6L4pnisXHnKMdFeigu92vHSrhTFyukx%2Bpx3Z%2BUIhddLRhOD8wEAX9cfFbQkSkXFkhdumtDGO%2BSOKHn3xOcV8WyW5cUsWTFhQ5I%2F5VsakDriT2fQajQKLAKtkP4q7E2CoFBhvs8tVOKvDzBMUWO9U8ieyYQMHAv3VNEXHHspwOD3VMw75aTKnKCTw8z4TktnGGZdZp5p2mf8&amp;TOPIC_ID=6509" target="_blank">
          letter to stakeholders
         </a>
         to raise awareness of the ubiquitous presence of xylazine in illicit drugs [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         In humans, xylazine overdose, alone and in combination with opioid intoxication, can cause major toxicity similar to
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and consisting of coma, apnea, bradycardia, and hypotension as well as severe, necrotic skin ulcerations  (
         <a class="graphic graphic_picture graphicRef141718" href="/z/d/graphic/141718.html" rel="external">
          picture 1
         </a>
         ) and abscesses after repeated parenteral use [
         <a href="#rid10">
          10,40,41,44,49
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          KINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The absorption, distribution, and elimination of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         vary depending upon the formulation of clonidine and route of exposure:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
          tablets
         </strong>
         – The pharmacokinetics for oral ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         tablets are as follows [
         <a href="#rid50">
          50-52
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bioavailability is 75 to 100 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peak plasma
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         concentrations occur at approximately 2 hours, and absorption is complete by 2.5 hours in hypertensive, fasting adults [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Maximal blood pressure reduction occurs between three and eight hours after a routine daily dose [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         in the bloodstream is 20 to 40 percent protein bound and has an apparent volume of distribution of 3.2 to 5.6 L/kg.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Elimination half-life in therapeutic use ranges from 6 to 24 hours with more than half excreted unchanged in the urine [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
          patch
         </strong>
         —
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         patch formulations are available in doses of 2.5, 5, and 7.5 mg contained in a timed matrix delivery system [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         is delivered at a constant rate over seven days.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The elimination half-life while the patch is adherent varies from 26 to 55 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Up to 75 percent of the total dose may remain in a
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         patch after seven days of use.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tetrahydrozoline
         </strong>
         — A child with central nervous system (CNS) depression, bradycardia, hypotension and hypothermia after
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ingestion was found to have a plasma concentration of 24 ng/mL measured three hours after ingestion; in that case series, the drug had an apparent elimination half-life of 4.4 hours [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         The history should include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specific agent
         </strong>
         – In young children, the parent/primary caregiver frequently provides the history of ingestion. If the ingestant is unknown, a history of glaucoma or hypertension in an adult patient or household member suggests a
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         exposure, as does a tablet or patch medication prescribed for behavioral disturbance in a pediatric patient or sibling. (See
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In older children, adolescents, or adults, any witnesses and emergency medical services (EMS) personnel who may have recovered pill bottles at the scene should be contacted. The patient's pharmacy may provide valuable information regarding prescribed medications, the date of the most recent refill, and the total number of pills dispensed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Xylazine is a common adulterant of heroin, illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , and other illegal drugs. The patient may not be aware that they are exposed to xylazine.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Type of exposure
         </strong>
         – For
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and related imidazolines, oral ingestion is most common, but transdermal exposure (eg, clonidine transdermal patch) is also described [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Any patient being treated for illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         or heroin poisoning via snorting or injection may also be exposed to xylazine as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For ingestions, amount ingested, time of ingestion, and any co-ingestions provide important information. A detailed knowledge of the patient's co-ingestants and chronic medications is essential because
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         exacerbates the hypotension of co-ingested antihypertensive medications (eg, beta blockers, calcium channel blockers) and the lethargy or coma following ingestion of ethanol, barbiturates, and other sedative hypnotics (eg, benzodiazepines,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         ,
         <a class="drug drug_general" data-topicid="9239" href="/z/d/drug information/9239.html" rel="external">
          chloral hydrate
         </a>
         ). The clinical approach to the poisoned patient is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cause of
         </strong>
         <strong>
          exposure
         </strong>
         – In young children, serious toxicity can occur with an exploratory ingestion of one to two
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         pills.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Major and life-threatening toxicity is more common when
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         is ingested with an intention for self-harm or xylazine exposure inadvertently occurs in combination with heroin or
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         overdose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medical history
         </strong>
         – It is also important to review the medical history for conditions that may predispose patients to the toxic effects of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , such as airway compromise or preexisting cardiac conduction abnormalities.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Physical examination
         </span>
        </p>
        <p class="headingAnchor" id="H2424529407">
         <span class="h3">
          Clonidine and imidazoline medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical findings and timing of toxicity vary by agent and preparation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         – The classic clonidine toxic syndrome, or "toxidrome” after ingestion consists of [
         <a href="#rid56">
          56-58
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Depressed mental status
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Miosis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Depressed respirations
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bradycardia and hypotension
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Signs of toxicity are usually appear soon after
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         tablet ingestion; new findings of poisoning rarely emerge more than four to eight hours after exposure [
         <a href="#rid55">
          55,57,58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         patch exposure through ingestion or self-application to the skin may result in signs of toxicity that develop several hours after exposure [
         <a href="#rid59">
          59,60
         </a>
         ]. A full body search for adherent transdermal patches including the skin, palate, anus, and genitalia should occur during physical examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Up to 60 percent of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         exposures that are reported to regional poison control centers result in signs or symptoms [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Depressed mental status
         </strong>
         – Depressed mental status, ranging from lethargy to coma, is the most common finding after
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning occurring in up to 90 percent of poisoned patients [
         <a href="#rid2">
          2,3,55,57,58,61
         </a>
         ]. Miosis, hyporeflexia, and hypotonia often accompany CNS depression and make the differentiation of clonidine poisoning from opioid toxicity difficult  (
         <a class="graphic graphic_table graphicRef56801" href="/z/d/graphic/56801.html" rel="external">
          table 1
         </a>
         ). Compared with individuals with opioid poisoning, patients with clonidine poisoning are more likely to respond transiently to painful stimuli.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Respiratory depression
         </strong>
         – Respiratory depression may accompany
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning and may include apnea. The frequency of respiratory depression in patients with clonidine poisoning ranges from 20 to over 50 percent of hospitalized pediatric patients and up to 5 percent of all exposures based on reports to regional poison control centers [
         <a href="#rid2">
          2,3,55,57,58,61
         </a>
         ]. It is less common in older children, adolescents, and adults. Children with apnea will often resume breathing with tactile stimulation. However, endotracheal intubation is occasionally necessary [
         <a href="#rid2">
          2,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bradycardia and hypotension
         </strong>
         – Bradycardia and hypotension are frequent signs of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and related imidazoline toxicity among children and are seen in up to 50 percent of hospitalized patients [
         <a href="#rid2">
          2,55
         </a>
         ]. Among adolescents and adults with clonidine poisoning, up to 75 percent of patients may develop bradycardia and 25 percent hypotension [
         <a href="#rid62">
          62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Depending upon the ingested dose, bradycardia may persist for hours to days. Sinus bradycardia is the usual rhythm, although atrioventricular (AV) block and sinus arrest have also been described [
         <a href="#rid63">
          63,64
         </a>
         ]. Second-degree AV block or complete AV dissociation are uncommon and should prompt consideration of toxicity from other cardioactive agents, such as
         <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">
          digoxin
         </a>
         , beta blockers, or calcium channel blockers  (
         <a class="graphic graphic_waveform graphicRef79539" href="/z/d/graphic/79539.html" rel="external">
          waveform 1
         </a>
         and
         <a class="graphic graphic_waveform graphicRef63951" href="/z/d/graphic/63951.html" rel="external">
          waveform 2
         </a>
         ).
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          Tizanidine
         </a>
         is notable because it may prolong the QT interval on electrocardiogram (ECG) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Other findings
         </strong>
         – Hypertension occurs transiently in many patients with
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         overdose, particularly after a large ingestion [
         <a href="#rid36">
          36,57
         </a>
         ]. In addition, hypertension has been reported in patients with clonidine poisoning who receive
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . Hypertension progressing to hypotension has also been reported after
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         overdose [
         <a href="#rid66">
          66
         </a>
         ]. Hypertensive emergency requiring treatment is very rare [
         <a href="#rid67">
          67
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pallor, hypothermia, and dry mouth may also occur after
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning [
         <a href="#rid57">
          57,68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Related imidazolines
         </strong>
         – Other imidazoline agents cause similar toxicity as
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         after exposure:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          Guanfacine
         </a>
         <strong>
          and guanabenz
         </strong>
         – Clinical features of regular-release guanfacine or guanabenz ingestion include lethargy, bradycardia, and hypotension [
         <a href="#rid2">
          2,9
         </a>
         ]. Respiratory depression has been described but appears to be less frequent with these agents than
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         [
         <a href="#rid2">
          2
         </a>
         ].The duration of effect is typically &lt;24 hours [
         <a href="#rid9">
          9
         </a>
         ]. Prolonged orthostatic hypotension has been described in a 12-year-old boy after poisoning with extended-release guanfacine [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imidazoline-containing eye and nose drops
         </strong>
         – In young children, ingestion or ocular exposure to liquid imidazoline preparations, such as ocular and nasal decongestants (
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9856" href="/z/d/drug information/9856.html" rel="external">
          naphazoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">
          oxymetazoline
         </a>
         , and
         <a class="drug drug_general" data-topicid="106757" href="/z/d/drug information/106757.html" rel="external">
          xylometazoline
         </a>
         ) or eye drops prescribed for glaucoma (
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          brimonidine
         </a>
         and
         <a class="drug drug_general" data-topicid="8863" href="/z/d/drug information/8863.html" rel="external">
          apraclonidine
         </a>
         ) can cause serious poisoning within 30 minutes [
         <a href="#rid26">
          26,28,29
         </a>
         ]. (See
         <a class="local">
          'Clonidine and other imidazoline medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          Tizanidine
         </a>
         – Poisoning with tizanidine has caused lethargy, coma, bradycardia, hypertension, and hypotension [
         <a href="#rid27">
          27,30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H745000022">
         <span class="h3">
          Xylazine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xylazine overdose has caused major toxicity consisting of coma, apnea, bradycardia, and hypotension after inhalation or intravenous (IV) administration with heroin or illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         [
         <a href="#rid10">
          10,13,14,40-44,49
         </a>
         ]. However, compared with opioid overdose alone, overdose of xylazine and an opioid was associated with a lower risk of cardiac arrest or coma in one multicenter cohort study [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Severe, necrotic skin ulcerations  (
         <a class="graphic graphic_picture graphicRef141718" href="/z/d/graphic/141718.html" rel="external">
          picture 1
         </a>
         ) and skin abscesses have also occurred after repeated parenteral use [
         <a href="#rid12">
          12,70-73
         </a>
         ]. These patients require drug use disorder support to stop injecting and using xylazine and specialized wound care as described separately. (See
         <a class="local">
          'Xylazine withdrawal'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/99040.html" rel="external">
          "Overview of treatment of chronic wounds"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1555197501">
         <span class="h2">
          Ancillary studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with altered mental status and suspected
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning, we recommend the following tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bedside glucose determination to exclude hypoglycemia as the cause of reduced consciousness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Venous or arterial blood gas combined with pulse oximetry to assess adequacy of ventilation in patients with serious and persistent respiratory depression.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         level in patients who ingest
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         with intent for self-harm.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum ethanol level to identify patients at a higher risk for coma and respiratory depression due to co-ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and ethanol.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ECG to evaluate for drug-induced cardiac electrical dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiography if the history or exam suggests the possibility of pulmonary aspiration.
        </p>
        <p>
        </p>
        <p>
         Other studies that may be helpful in selected patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolyte determination, in the setting of co-ingestants, to assess for electrolyte disturbance or metabolic acidosis and to calculate the anion gap.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum blood urea nitrogen and creatinine to identify patients with renal insufficiency who may have delayed elimination of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         after overdose.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rapid urine pregnancy test in post-menarcheal women.
        </p>
        <p>
        </p>
        <p>
         Quantitative and qualitative testing for
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         is available from dedicated toxicology reference laboratories with methodology, such as gas chromatography or mass spectroscopy. However, the results usually cannot be obtained in time to be useful for patient management. Thus, specific measurement of clonidine in the urine or other fluids is typically performed for forensic or other non-clinical purposes and is not routine.
        </p>
        <p>
         Similarly, rapid hospital-based tests for xylazine are usually not available, but it may be detected by specific analytical testing. In addition, test strips can detect xylazine in liquid or powder illicit drug samples with high sensitivity and specificity [
         <a href="#rid47">
          47,74
         </a>
         ]. The strips are available for use by overdose outreach workers, forensic laboratories, and prehospital personnel.
        </p>
        <p>
         For asymptomatic patients, the need for laboratory evaluation of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning varies depending on the circumstances of exposure. For example, a witnessed exploratory ingestion in a toddler or a known therapeutic error in a hospitalized patient may merit little laboratory investigation, whereas an unwitnessed ingestion with intent of self-harm may warrant more extensive testing, especially if clonidine is not the definite cause of symptoms. Other ancillary studies may be indicated in selected patients in whom trauma, infection, or other etiologies besides poisoning are suspected. (See
         <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">
          "Evaluation of stupor and coma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">
          "Stupor and coma in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1835879123">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , xylazine, or related imidazoline poisoning relies upon clinical findings obtained from a careful history that indicates a confirmed or suspected exposure to an imidazoline and a physical examination that has a combination of  (
         <a class="graphic graphic_table graphicRef63110" href="/z/d/graphic/63110.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Clinical features'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lethargy, coma, and small pupils (miosis)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory depression
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bradycardia and hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Transient hypertension followed by hypotension
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with suspected chronic xylazine use, severe necrotic skin lesions  (
         <a class="graphic graphic_picture graphicRef141718" href="/z/d/graphic/141718.html" rel="external">
          picture 1
         </a>
         ) and/or skin abscesses
        </p>
        <p>
        </p>
        <p>
         For patients with suspected or confirmed overdoses of heroin or illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         , lack of responsiveness to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         therapy may suggest co-administration of xylazine [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are many causes of coma that deserve consideration when evaluating the patient with suspected
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning  (
         <a class="graphic graphic_table graphicRef65571" href="/z/d/graphic/65571.html" rel="external">
          table 3
         </a>
         ). In the poisoned patient, it is especially important to consider hypoglycemia and potential traumatic brain injury. (See
         <a class="medical medical_review" href="/z/d/html/6225.html" rel="external">
          "Evaluation of stupor and coma in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5104.html" rel="external">
          "Stupor and coma in adults"
         </a>
         .)
        </p>
        <p>
         As in all poisonings, the clinician should determine the potential for co-ingested toxic agents.
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         exacerbates the lethargy or coma following ingestion of opioids, ethanol, benzodiazepines,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         , barbiturates, and other sedative hypnotics. (See
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         .)
        </p>
        <p>
         Among toxic agents that may cause coma, the centrally acting, though chemically distinct, anti-hypertensive medication
         <a class="drug drug_general" data-topicid="9635" href="/z/d/drug information/9635.html" rel="external">
          methyldopa
         </a>
         also decrease sympathetic outflow and mimic
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         's toxic effects. In patients with a history of heroin or
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         use, xylazine may be an adulterant and contribute to the toxicity of these illicit drugs. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Opioid adulterants, including krokodil'
         </a>
         .)
        </p>
        <p>
         The combination of central nervous system depression and pupillary miosis closely resembles the toxic syndrome seen with opioid intoxication, which may be further confused by the variable response of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (
         <a class="graphic graphic_table graphicRef56801" href="/z/d/graphic/56801.html" rel="external">
          table 1
         </a>
         ). Many other sedative-hypnotic and psychoactive agents may also produce somnolence and bradycardia. Xylazine poisoning is suggested in patients with suspected opioid poisoning who have a suboptimal response to naloxone administration [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6504.html" rel="external">
          "Opioid intoxication in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1134300444">
         <span class="h2">
          Symptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         A rapid overview summarizes the initial management of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         and imidazoline poisoning  (
         <a class="graphic graphic_table graphicRef63110" href="/z/d/graphic/63110.html" rel="external">
          table 2
         </a>
         ). The management for patients with symptomatic clonidine and related imidazoline poisoning primarily consists of attentive supportive care with decontamination, as indicated. (See
         <a class="local">
          'Decontamination'
         </a>
         below.)
        </p>
        <p>
         For patients with xylazine poisoning, additional considerations may include acute management of concurrent opioid poisoning. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Management'
         </a>
         .)
        </p>
        <p>
         Consultation with a clinical toxicologist is available to provide guidance in managing individual patients. To obtain emergency consultation with a medical toxicologist, in the United States, call 1-800-222-1222, or the nearest international regional poison center. Contact information for poison control centers around the world is available at the WHO
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fdata%2Fgho%2Fdata%2Fthemes%2Ftopics%2Findicator-groups%2Fpoison-control-and-unintentional-poisoning&amp;token=jpAIr1tlk%2FvXPa%2FdZ4oXKNBAWFoLSTYd8RsKYQiAYU4tfQhQTwAATvRlmNRf780yA02NrpzDgycoMLk%2BSeDbdZHGFNcNlcKU3%2Fwo1O4aYliGYTL5DWesMOS3dOA1mPxr&amp;TOPIC_ID=6509" target="_blank">
          website
         </a>
         and separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4246119796">
         <span class="h3">
          Coma with respiratory depression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Coma with respiratory depression often responds transiently to tactile stimulation of the patient.
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          Naloxone
         </a>
         has been utilized to treat seriously poisoned patients with inconsistent results. For patients with suspected
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , xylazine, or related imidazoline poisoning and with marked central nervous system (CNS) depression and respiratory depression, we suggest a trial of intravenous (IV) naloxone, However, clinicians should proceed with endotracheal intubation and mechanical ventilation if there is no immediate response to naloxone and there is any doubt about the patient's ability to breathe adequately on their own or protect their airway.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Naloxone
         </strong>
         — The dose of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         depends upon the patient's suspected tolerance to opioids  (
         <a class="graphic graphic_table graphicRef63110" href="/z/d/graphic/63110.html" rel="external">
          table 2
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Opioid-naïve patients
         </strong>
         – For opioid-naïve patients, the dose is 0.1 mg/kg, maximum single dose: 2 mg; which may be repeated every one to two minutes up to a total dose of 10 mg. Clinicians particularly knowledgeable of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         pharmacology and of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning physiology might consider higher maximum single doses, especially in children [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Opioid-tolerant patients
         </strong>
         – For opioid-tolerant patients, the dose depends upon respiratory status.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Apneic patients: Initial dose 0.2 to 1 mg, repeat if no response (maximum total dose 10 mg).
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Patients with spontaneously respirations and pulse oximetry &lt;90 percent: Initial dose 0.04 mg IV and repeat until respiratory rate is in the normal range (maximum total dose 10 mg).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          Naloxone
         </a>
         dosing in patients with suspected opioid tolerance is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Basic measures and antidotal therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Many patients who respond to the initial dose of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         do not require additional doses [
         <a href="#rid57">
          57
         </a>
         ]. However, if altered mental status and respiratory depression recur, we suggest the administration of additional intermittent doses as needed, rather than a continuous infusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Regardless of dose used, patients not responding to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         treatment should receive timely provision of supportive care of airway and breathing. Patients who improve after naloxone administration still warrant hospital admission and intensive monitoring for recurrence of symptoms. Although generally safe, naloxone therapy for
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         overdose has rarely been associated with the onset of acute hypertension [
         <a href="#rid5">
          5,75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence regarding the benefit of
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         for reversal of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         toxicity is limited, and some experts do not routinely recommend naloxone for clonidine and imidazoline poisoning, especially in adolescents and adults [
         <a href="#rid76">
          76
         </a>
         ]. In case reports and case series, IV naloxone administration at a dose of 0.05 to 0.1 mg/kg (maximum single dose 10 mg) has reversed signs of clonidine,
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         poisoning in some pediatric patients [
         <a href="#rid5">
          5,56-58,77-80
         </a>
         ]. In one of the largest studies (51 children), naloxone reversed depressed mental status in approximately 80 percent of patients; a single dose of 10 mg did not appear to increase the rate of response compared to 6 mg or less [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, in a cohort of 108 adolescent and adult patients with
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning,
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (dose range 0.1 to 14 mg) was
         <strong>
          not
         </strong>
         found to result in improvement of Glasgow Coma Scale (GCS) unless concomitant opioid poisoning was suspected [
         <a href="#rid62">
          62
         </a>
         ]. Experience with naloxone administration for related imidazolines in adults is limited [
         <a href="#rid58">
          58
         </a>
         ]. An adult with
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         poisoning had improved mental status after high-dose (10mg IV) naloxone with minimal improvement in bradycardia [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medications to avoid
         </strong>
         — The nonselective alpha adrenergic antagonist, tolazoline, and the specific alpha-2 adrenergic antagonist, yohimbine, were proposed in the past as potential antidotes for
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoning [
         <a href="#rid81">
          81,82
         </a>
         ], but the risk associated with these agents exceeds any expected benefit [
         <a href="#rid57">
          57,81,83,84
         </a>
         ]. Thus, we strongly discourage the use of these agents for treatment of clonidine or xylazine poisoning.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The selective alpha-1 adrenergic antagonist
         <a class="drug drug_general" data-topicid="9767" href="/z/d/drug information/9767.html" rel="external">
          phentolamine
         </a>
         would be expected to promote hypotension and should also be avoided.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H55446950">
         <span class="h3">
          Bradycardia and hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to bradycardia and hypotension includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bradycardia
         </strong>
         – Bradycardia is typically mild and associated with signs of good tissue perfusion and, in these patients, requires no specific treatment. Patients with bradycardia and hypotension require rapid supportive care to restore adequate heart rate and blood pressure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For treatment of bradycardia, we suggest IV
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , although other chronotropic treatments are reasonable options. For patients who improve after atropine administration, the response may be short-lived, and redosing of atropine may be needed until toxicity resolves [
         <a href="#rid62">
          62
         </a>
         ]. Based upon case reports and case series in children and adults, when bradycardia compromises circulation, it is often responsive to atropine [
         <a href="#rid57">
          57,62
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who do not respond to
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         and continue to have circulatory impairment should receive treatment for bradycardia per Advanced Cardiac Life Support (adults,  (
         <a class="graphic graphic_algorithm graphicRef130748" href="/z/d/graphic/130748.html" rel="external">
          algorithm 1
         </a>
         )) or Pediatric Advanced Life Support (children,  (
         <a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">
          algorithm 2
         </a>
         )).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypotension
         </strong>
         – Hypotension usually resolves with improvement in mental status (comatose patients) or reversal of severe bradycardia [
         <a href="#rid55">
          55
         </a>
         ]. Hypotension that persists despite treatment of bradycardia may initially be treated with Trendelenburg positioning and rapid administration of IV isotonic crystalloid fluids (normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or Ringer's lactate solution). Continuous infusion of epinephrine, or similar agents such as norepinephrine or
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         , may be useful in the rare patient with persistent shock that is refractory despite treatment of bradycardia and fluid resuscitation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2501534293">
         <span class="h3">
          Hypertension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypertension may be noted early after
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         overdose and reflects peripheral alpha-2 adrenergic-mediated vasoconstriction. Hypertension is typically of short duration and is often followed by hypotension. Thus, in most patients, hypertension treatment is unnecessary and may be harmful.
        </p>
        <p>
         In the unlikely event that hypertension becomes symptomatic and must be treated, a short-acting, easily titratable agent such as
         <a class="drug drug_general" data-topicid="9707" href="/z/d/drug information/9707.html" rel="external">
          nitroprusside
         </a>
         is advised. Beta adrenergic antagonist agents should be avoided because they may lead to unopposed alpha-adrenergic action with worsening of hypertension. (See
         <a class="medical medical_review" href="/z/d/html/3837.html" rel="external">
          "Evaluation and treatment of hypertensive emergencies in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6438.html" rel="external">
          "Approach to hypertensive emergencies and urgencies in children"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H623818478">
         <span class="h3">
          Hypothermia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypothermia is typically mild and responds to external warming such as forced air rewarming, warm blankets, or radiant heat lamps. (See
         <a class="medical medical_review" href="/z/d/html/178.html" rel="external">
          "Accidental hypothermia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6598.html" rel="external">
          "Hypothermia in children: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2456738791">
         <span class="h2">
          Asymptomatic patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the initially asymptomatic patient with a potentially toxic
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or related imidazoline medication exposure depends upon the preparation and type of exposure  (
         <a class="graphic graphic_algorithm graphicRef141211" href="/z/d/graphic/141211.html" rel="external">
          algorithm 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ingestion of regular-release tablets or liquid preparations
         </strong>
         – Management of patients who are asymptomatic after a potentially toxic ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , regular-release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         , or liquid preparations (such as
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">
          oxymetazoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9856" href="/z/d/drug information/9856.html" rel="external">
          naphazoline
         </a>
         , or
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          brimonidine
         </a>
         ) is provided in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141211" href="/z/d/graphic/141211.html" rel="external">
          algorithm 3
         </a>
         ). Administration of activated charcoal is suggested, followed by observation for at least six hours. Patients who are asymptomatic at six hours are unlikely to develop serious toxicity and may be medically cleared for mental health evaluation (intended self-harm) or discharged home, although ability for close observation and timely return if symptoms developed must be assured.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ingestion of a transdermal
         </strong>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         <strong>
          patch
         </strong>
         – Asymptomatic patients who ingest a transdermal clonidine patch are at risk for delayed and ongoing toxicity until the patch has passed out of the gastrointestinal tract [
         <a href="#rid59">
          59
         </a>
         ]. They require decontamination as described separately and admission for observation. (See
         <a class="local">
          'Clonidine patch'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transdermal patch on skin
         </strong>
         – For asymptomatic patients with a transdermal exposure, patch removal is the most important intervention. These patients should undergo careful and full examination of the patient’s skin removal of all adherent patches, and careful history to exclude ingestion of a transdermal patch. Once accomplished, these patients may be discharged home, or, if the exposure was intended for self-harm, medically cleared for mental health evaluation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4051397842">
         <span class="h1">
          DECONTAMINATION
         </span>
        </p>
        <p class="headingAnchor" id="H767200531">
         <span class="h2">
          Cutaneous decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         All patients with signs of potential
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or imidazoline poisoning warrant careful examination and removal of any adherent transdermal patch from the skin, palate, genitalia, or anus.
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Gastrointestinal decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         and related imidazolines bind well to activated charcoal (AC), the primary means of decontamination after drug overdose. Whole bowel irrigation (WBI) is suggested in patients who ingest a transdermal clonidine patch. Gastric emptying by gastric lavage or by syrup of ipecac-induced emesis in patients who ingest clonidine or related imidazolines should be avoided because of minimal benefit and risk of aspiration for patients who undergo gastric emptying after poisoning. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Tablet or liquid preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who present within one hour of a known or suspected ingestion of a potentially toxic dose of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         tablets or regular-release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         or within 30 minutes of ingestion of an imidazoline liquid preparation, we suggest AC (1 g/kg, maximum dose 50 g) by mouth or nasogastric tube. Great care must be taken to ensure that the airway is not compromised prior to administration and that pulmonary aspiration risk be minimized. Patients with respiratory depression or coma should first have their airway secured as needed based on clinical evaluation prior to AC administration.
        </p>
        <p>
         For patients who present for care more than one hour after ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , regular release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         , or liquid imidazoline preparations, the likelihood of preventing medication absorption is low outweighed by the risk of pulmonary aspiration.
        </p>
        <p>
         The recommendation for AC administration following
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         overdose derives from indirect evidence of benefit in volunteers, animal studies, and evidence of benefit following ingestions of other medications [
         <a href="#rid85">
          85,86
         </a>
         ]. Because of adverse effects such as vomiting and dehydration, the combination of a cathartic (eg,
         <a class="drug drug_general" data-topicid="9940" href="/z/d/drug information/9940.html" rel="external">
          sorbitol
         </a>
         ) and AC should be used sparingly if at all, and only a single dose of a cathartic should be given to any patient. This approach is especially pertinent after clonidine ingestion because sedation and coma are common. The greatest benefit occurs if AC is given within one hour. The efficacy of AC as a function of time from ingestion is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient", section on 'Evidence of efficacy and adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Clonidine patch
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the initial assessment, patients with patch ingestion or exposure should be undressed, and any adherent transdermal patches removed. For patients who have ingested a
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         transdermal patch, we suggest the nasogastric administration of WBI (500 mL to 1 L of polyethylene glycol per hour) after oral or nasogastric administration of AC (1 g/kg, maximum dose 50 g). In this setting, AC may also prevent delayed absorption of clonidine when administered more than one hour after ingestion. Safe administration of WBI requires the following [
         <a href="#rid87">
          87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Airway adequacy must be assessed and if it is inadequate, it should be secured prior to the procedure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient should have bowel sounds present and no evidence of gastrointestinal obstruction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nasogastric tube placement must be confirmed by radiograph or bedside ultrasonography prior to initiation of WBI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient should be maintained in an upright position (minimum 45-degree elevation of the head) throughout the procedure.
        </p>
        <p>
        </p>
        <p>
         Gastrointestinal decontamination is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/321.html" rel="external">
          "Gastrointestinal decontamination of the poisoned patient"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2300651077">
         <span class="h1">
          EXTRACORPOREAL REMOVAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         is not amenable to extracorporeal removal including multiple dose activated charcoal, hemodialysis, or hemoperfusion.
        </p>
        <p class="headingAnchor" id="H3179834899">
         <span class="h1">
          DISPOSITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Further management depends on the presence of symptoms and circumstances for the ingestion  (
         <a class="graphic graphic_algorithm graphicRef141211" href="/z/d/graphic/141211.html" rel="external">
          algorithm 3
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Symptomatic patients
         </strong>
         — All patients displaying
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or related imidazoline toxicity warrant hospital admission and intensive medical care regardless of their response to
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         . These patients often fully recover within 24 to 48 hours. Bradycardia and hypotension associated with extended-release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         poisoning may be prolonged [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Asymptomatic patients
         </strong>
         — Disposition of asymptomatic patients depends upon the
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         formulation ingested:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Oral imidazoline tablets or liquid preparations
         </strong>
         – Patients who remain asymptomatic at six hours after exploratory or inadvertent ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or related imidazoline tablets (as well as imidazoline liquids) may be discharged home as long as close observation and ability to rapidly return for medical care, if needed, is assured. Extended release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         formulations may warrant longer observation periods.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
          patch
         </strong>
         – Asymptomatic patients who ingest a
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         transdermal patch should undergo gastrointestinal decontamination and be admitted for close monitored because signs of poisoning may be delayed for up to 24 hours [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="local">
          'Clonidine patch'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Intentional overdose
         </strong>
         – Patients who ingest
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or related imidazolines with intent of self-harm warrant mental health consultation, measurement of serum
         <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">
          acetaminophen
         </a>
         levels, and careful evaluation for other co-ingestants. (See
         <a class="local">
          'Ancillary studies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         These individuals warrant mental health evaluation before discharge from medical care. Psychiatric evaluation should be deferred in symptomatic patients until after they have recovered. (See
         <a class="medical medical_review" href="/z/d/html/6496.html" rel="external">
          "Approach to the child with occult toxic exposure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/324.html" rel="external">
          "General approach to drug poisoning in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30">
         <span class="h1">
          ADDITIONAL PEDIATRIC CONSIDERATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         is frequently prescribed for behavior problems in children. Clonidine exposure often involves young children who ingest their own medication or that of another child in the household [
         <a href="#rid55">
          55,57,61
         </a>
         ]. Ingestion of as little as one clonidine tablet or one swallow of imidazoline containing eye drops has been associated with life-threatening toxicity in children, but fortunately pediatric deaths are rare and typically associated with large-dose exposures [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In addition to routine anticipatory guidance regarding poisoning prevention, clinicians should counsel caretakers about measures to prevent
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or imidazoline poisonings as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Used transdermal
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         patch preparations contain a significant amount of clonidine. These patches should be carefully discarded so that young children cannot find them in the trash. Caretakers should be alerted to the serious toxicity these patches pose if ingested or reapplied to the skin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Topical imidazoline preparations such as eye or nose drops containing
         <a class="drug drug_general" data-topicid="10280" href="/z/d/drug information/10280.html" rel="external">
          tetrahydrozoline
         </a>
         ,
         <a class="drug drug_general" data-topicid="10186" href="/z/d/drug information/10186.html" rel="external">
          oxymetazoline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9163" href="/z/d/drug information/9163.html" rel="external">
          brimonidine
         </a>
         , are tasteless and highly potent after ingestion. They often do not have child-resistant closures and need to be kept out of reach of children. (See
         <a class="medical medical_review" href="/z/d/html/2873.html" rel="external">
          "Prevention of poisoning in children", section on 'Anticipatory guidance'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2879257045">
         <span class="h1">
          XYLAZINE WITHDRAWAL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Xylazine has entered the illicit drug supply, and xylazine poisoning has become an important public health issue [
         <a href="#rid89">
          89
         </a>
         ]. (See
         <a class="local">
          'Xylazine'
         </a>
         above.)
        </p>
        <p>
         As xylazine use has increased, xylazine withdrawal has been described [
         <a href="#rid90">
          90,91
         </a>
         ]. In a 2022 study using an internet survey of 61 individuals who admitted to xylazine use alone or with opioids, about one-half of the respondents reported experiencing xylazine withdrawal [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Reported findings of xylazine withdrawal include [
         <a href="#rid90">
          90,91
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Irritability
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Craving
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Anxiety
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dysphoria
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Tachycardia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypertension
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Body aches
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to these symptoms, almost 60 percent of survey respondents described worsening withdrawal from opioids or other substances with some also reporting lowered perceived effectiveness of
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         or
         <a class="drug drug_general" data-topicid="9170" href="/z/d/drug information/9170.html" rel="external">
          buprenorphine
         </a>
         to control opioid withdrawal [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – There are no established criteria for the diagnosis of xylazine withdrawal [
         <a href="#rid12">
          12
         </a>
         ]. The clinical findings described by users overlap with opioid withdrawal likely due to co-use with opioids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Evidence is lacking regarding the management of xylazine withdrawal. Consultation with an addiction specialist or medical toxicologist is advised.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential replacement oral agents include
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9999" href="/z/d/drug information/9999.html" rel="external">
          tizanidine
         </a>
         , and
         <a class="drug drug_general" data-topicid="117925" href="/z/d/drug information/117925.html" rel="external">
          lofexidine
         </a>
         [
         <a href="#rid89">
          89
         </a>
         ]. In a case report of one patient with opioid use disorder and chronic xylazine use, successful treatment of withdrawal symptoms included a combination of continuous
         <a class="drug drug_general" data-topicid="8897" href="/z/d/drug information/8897.html" rel="external">
          dexmedetomidine
         </a>
         infusion,
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         for autonomic symptoms, and tizanidine, which was later changed to oral clonidine to better control residual symptoms (rigors) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who report chronic xylazine use require careful evaluation to identify other agents that may be contributing to clinical findings of withdrawal including opioids, alcohol, and/or benzodiazepines and initiate appropriate treatment as described separately [
         <a href="#rid12">
          12
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/306.html" rel="external">
          "Opioid withdrawal in the emergency setting"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7808.html" rel="external">
          "Opioid withdrawal: Medically supervised withdrawal during treatment for opioid use disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/323.html" rel="external">
          "Management of moderate and severe alcohol withdrawal syndromes"
         </a>
         .)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">
          "Benzodiazepine withdrawal"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H1023217114">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2044862910">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112689.html" rel="external">
          "Society guideline links: General measures for acute poisoning treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H32">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rapid overview
         </strong>
         – A rapid overview table provides the common clinical features and essential initial management of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or related imidazoline poisoning  (
         <a class="graphic graphic_table graphicRef63110" href="/z/d/graphic/63110.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above and
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients with xylazine poisoning, additional considerations may include acute management of concurrent opioid poisoning. (See
         <a class="medical medical_review" href="/z/d/html/300.html" rel="external">
          "Acute opioid intoxication in adults", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Related imidazolines that have similar properties and toxicity as
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         are provided in the graphic  (
         <a class="graphic graphic_algorithm graphicRef141211" href="/z/d/graphic/141211.html" rel="external">
          algorithm 3
         </a>
         ). Ingestion of as little as one clonidine tablet or one swallow of imidazoline-containing eye drops is a serious exposure in young children. Xylazine poisoning, alone and in combination with heroin or illicit
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         poisoning, can cause major toxicity and death. (See
         <a class="local">
          'Clonidine and other imidazoline medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         –
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          Clonidine
         </a>
         , xylazine, and related imidazoline poisoning is a clinical diagnosis based upon a history of suspected or confirmed exposure and clinical features of poisoning (ie, lethargy/coma with miosis, depressed respirations, bradycardia and hypotension, and/or transient hypertension). (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Poisoning often develops within one hour of ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or regular release tablet formulations of other imidazolines; new findings rarely appear more than four to eight hours after ingestion. In young children, ingestion or ocular exposure to liquid imidazoline preparations, such as ocular and nasal decongestants or eye drops prescribed for glaucoma can cause serious poisoning within 30 minutes. Clonidine patch ingestion or self-application to the skin may cause delayed toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of symptomatic patients
         </strong>
         – Most
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         poisoned patients will have good outcomes with attentive supportive care of airway, breathing, and circulation. (See
         <a class="local">
          'Symptomatic patients'
         </a>
         above.):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Coma with respiratory depression
         </strong>
         – For patients with suspected
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , xylazine, or related imidazoline poisoning and coma with respiratory depression, we suggest a trial of intravenous (IV)
         <a class="drug drug_general" data-topicid="9678" href="/z/d/drug information/9678.html" rel="external">
          naloxone
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The dose of naloxone depends upon the patient’s suspected tolerance to opioids  (
         <a class="graphic graphic_table graphicRef63110" href="/z/d/graphic/63110.html" rel="external">
          table 2
         </a>
         ). In patients who do not respond, further naloxone treatment should
         <strong>
          not
         </strong>
         delay the timely provision of supportive care for coma, respiratory depression, and/or circulatory impairment. The benefit of naloxone in patients with clonidine or related imidazoline poisoning is uncertain and some experts do not routinely use naloxone in this setting, especially in adult patients. (See
         <a class="local">
          'Coma with respiratory depression'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bradycardia and hypotension
         </strong>
         – Patients with bradycardia and hypotension require rapid supportive care to restore adequate heart rate and blood pressure (see
         <a class="local">
          'Bradycardia and hypotension'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Bradycardia
         </strong>
         – For patients with bradycardia associated with poor perfusion, we suggest IV
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         as the first-line agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Epinephrine is a reasonable alternative. For patients who improve after atropine administration, the response may be short-lived and atropine redosing may be needed until toxicity resolves. Patients who do not respond to atropine should receive treatment for bradycardia per Advanced Cardiac Life Support (adults,  (
         <a class="graphic graphic_algorithm graphicRef130748" href="/z/d/graphic/130748.html" rel="external">
          algorithm 1
         </a>
         )) or Pediatric Advanced Life Support (children,  (
         <a class="graphic graphic_algorithm graphicRef129941" href="/z/d/graphic/129941.html" rel="external">
          algorithm 2
         </a>
         )).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Hypotension
         </strong>
         – Hypotension usually resolves with reversal of bradycardia or, in comatose patients, improvement in mental status. Patients with persistent hypotension require Trendelenburg positioning and rapid administration of intravenous isotonic crystalloid fluids (normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or Ringer's lactate solution). In the rare patient with refractory shock despite initial fluid resuscitation, continuous infusion of epinephrine or similar agents such as norepinephrine or
         <a class="drug drug_general" data-topicid="9384" href="/z/d/drug information/9384.html" rel="external">
          dopamine
         </a>
         are warranted. (See
         <a class="medical medical_review" href="/z/d/html/6397.html" rel="external">
          "Shock in children in resource-abundant settings: Initial management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/98976.html" rel="external">
          "Evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypertension
         </strong>
         – Because hypertension is usually transient, treatment is unnecessary and may be harmful. (See
         <a class="local">
          'Hypertension'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of
         </strong>
         <strong>
          asymptomatic patients
         </strong>
         – Management of patients who are asymptomatic after a potentially toxic ingestion of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         , xylazine, or related imidazolines is provided in the algorithm  (
         <a class="graphic graphic_algorithm graphicRef141211" href="/z/d/graphic/141211.html" rel="external">
          algorithm 3
         </a>
         ).These patients require decontamination, as summarized below, and observation for at least six hours to see if signs of poisoning develop. (See
         <a class="local">
          'Asymptomatic patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Decontamination
         </strong>
         – All patients with potential
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         or imidazoline poisoning warrant careful examination and removal of any adherent transdermal patches from the skin, palate, genitalia, or anus. (See
         <a class="local">
          'Cutaneous decontamination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         After initial assessment and stabilization, performance of gastrointestinal decontamination depends upon the time since ingestion and/or specific preparation ingested (see
         <a class="local">
          'Gastrointestinal decontamination'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
          tablet or imidazoline preparation ingestion
         </strong>
         – For patients who present within one hour of a known or suspected ingestion of a potentially toxic dose of
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         tablets or regular-release
         <a class="drug drug_general" data-topicid="8510" href="/z/d/drug information/8510.html" rel="external">
          guanfacine
         </a>
         or within 30 minutes of ingestion of an imidazoline liquid preparation, we suggest activated charcoal (AC, 1 g/kg, maximum dose 50 g) by mouth or nasogastric tube (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). AC should be withheld in patients who are sedated and unable to protect their airway unless endotracheal intubation is performed first. However, endotracheal intubation should not be performed solely for the purpose of giving AC. (See
         <a class="local">
          'Tablet or liquid preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Clonidine
         </strong>
         <strong>
          transdermal patch ingestion
         </strong>
         – For patients who have ingested a
         <a class="drug drug_general" data-topicid="9285" href="/z/d/drug information/9285.html" rel="external">
          clonidine
         </a>
         transdermal patch, we suggest oral or nasogastric administration of AC followed by whole bowel irrigation (WBI) (500 mL to 1 L of polyethylene glycol per hour) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In these patients, AC may also prevent delayed absorption of clonidine when administered more than one hour after ingestion. Prior to starting WBI, endotracheal intubation may be necessary in symptomatic patients to reduce the risk of aspiration. In addition, gastrointestinal integrity must be assured. (See
         <a class="local">
          'Clonidine patch'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H75255106">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The editorial staff at UpToDate acknowledge Kevin C Osterhoudt, MD, MS, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Lowenstein J. Drugs five years later: clonidine. Ann Intern Med 1980; 92:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GS, Le Lait MC, Heard K. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System. J Pediatr 2014; 164:149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med 2002; 156:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauchamp GA, Giffin SL, Horowitz BZ, et al. Poisonings Associated with Intubation: US National Poison Data System Exposures 2000-2013. J Med Toxicol 2016; 12:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seger DL, Loden JK. Naloxone reversal of clonidine toxicity: dose, dose, dose. Clin Toxicol (Phila) 2018; 56:873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cairns R, Brown JA, Buckley NA. Clonidine exposures in children under 6 (2004-2017): a retrospective study. Arch Dis Child 2019; 104:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lovegrove MC, Mathew J, Hampp C, et al. Emergency hospitalizations for unsupervised prescription medication ingestions by young children. Pediatrics 2014; 134:e1009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gummin DD, Mowry JB, Beuhler MC, et al. 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report. Clin Toxicol (Phila) 2020; 58:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winograd EJ, Sollee D, Schauben JL, et al. Pediatric guanfacine exposures reported to the National Poison Data System, 2000-2016. Clin Toxicol (Phila) 2020; 58:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller AA, Osterhoudt KC, Wingert W. Heroin: what's in the mix? Ann Emerg Med 2007; 50:352.
          </a>
         </li>
         <li class="breakAll">
          Moraff C. "'Tranq Dope' – The heroin combo that’s been putting Philly to sleep". Filter 2019; Apr 2. https://filtermag.org/tranq-dope-the-heroin-combo-thats-been-putting-philly-to-sleep/ (Accessed on December 12, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Orazio J, Nelson L, Perrone J, et al. Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review. Ann Intern Med 2023; 176:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson J, Pizzicato L, Johnson C, Viner K. Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019. Inj Prev 2021; 27:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend 2022; 233:109380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishina K, Mikawa K, Uesugi T, et al. Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature. Anesthesiology 2002; 96:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riordan CE, Kleber HD. Rapid opiate detoxification with clonidine and naloxone. Lancet 1980; 1:1079.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanley KM, Worrall CL, Lunsford SL, et al. Experience with an adult alcohol withdrawal syndrome practice guideline in internal medicine patients. Pharmacotherapy 2005; 25:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glassman AH, Stetner F, Walsh BT, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 1988; 259:2863.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clayden JR, Bell JW, Pellard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br Med J 1974; 9:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen V, Tiemann D, Park E, Salehi A. Alpha-2 Agonists. Anesthesiol Clin 2017; 35:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette's syndrome. Lancet 1979; 2:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazell PL, Stuart JE. A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. J Am Acad Child Adolesc Psychiatry 2003; 42:886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schnoes CJ, Kuhn BR, Workman EF, Ellis CR. Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance. Clin Pediatr (Phila) 2006; 45:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995; 34:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rangan C, Everson G, Cantrell FL. Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings. Pediatr Emerg Care 2008; 24:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiller HA, Bosse GM, Adamson LA. Retrospective review of Tizanidine (Zanaflex) overdose. J Toxicol Clin Toxicol 2004; 42:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lai Becker M, Huntington N, Woolf AD. Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote. Pediatrics 2009; 123:e305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghaffari Z, Zakariaei Z, Ghazaeian M, et al. Adverse effects of brimonidine eye drop in children: A case series. J Clin Pharm Ther 2021; 46:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams A, Copley C. High dose naloxone for acute tizanidine overdose in the emergency department: a case report. Clin Toxicol (Phila) 2021; 59:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eddy O, Howell JM. Are one or two dangerous? Clonidine and topical imidazolines exposure in toddlers. J Emerg Med 2003; 25:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbuto AF, Burns MM. Clonidine Compounding Error: Bradycardia and Sedation in a Pediatric Patient. J Emerg Med 2020; 59:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics 2001; 108:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver Rotellar JA, Sedano Monasterio E, Sabate de la Cruz J, Gausi Gene C. Clonidine in thousand-fold overdose. Lancet 1981; 1:1312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al-Abri SA, Yang HS, Olson KR. Unintentional pediatric ophthalmic tetrahydrozoline ingestion: case files of the medical toxicology fellowship at the University of California, San Francisco. J Med Toxicol 2014; 10:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seger DL. Clonidine toxicity revisited. J Toxicol Clin Toxicol 2002; 40:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Head GA, Gundlach AL, Musgrave IF. Recent advances in imidazoline receptor research: ligands--localization and isolation--signaling--functional and clinical studies. J Auton Nerv Syst 1998; 72:74.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talke PO, Caldwell JE, Richardson CA, Heier T. The effects of clonidine on human digital vasculature. Anesth Analg 2000; 91:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowry JA, Brown JT. Significance of the imidazoline receptors in toxicology. Clin Toxicol (Phila) 2014; 52:454.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Capraro AJ, Wiley JF 2nd, Tucker JR. Severe intoxication from xylazine inhalation. Pediatr Emerg Care 2001; 17:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehn BM. Assessing a Veterinary Sedative's Role in Drug Overdose Deaths. JAMA 2021; 326:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander RS, Canver BR, Sue KL, Morford KL. Xylazine and Overdoses: Trends, Concerns, and Recommendations. Am J Public Health 2022; 112:1212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kacinko SL, Mohr ALA, Logan BK, Barbieri EJ. Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework. J Anal Toxicol 2022; 46:911.
          </a>
         </li>
         <li class="breakAll">
          FDA alerts health care professionals of risks to patients exposed to xylazine in illicit drugs. US Food &amp; Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-risks-patients-exposed-xylazine-illicit-drugs (Accessed on November 10, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunez J, DeJoseph ME, Gill JR. Xylazine, a Veterinary Tranquilizer, Detected in 42 Accidental Fentanyl Intoxication Deaths. Am J Forensic Med Pathol 2021; 42:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Love JS, Levine M, Aldy K, et al. Opioid overdoses involving xylazine in emergency department patients: a multicenter study. Clin Toxicol (Phila) 2023; 61:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin R. Here's What to Know About Xylazine, aka Tranq, the Animal Tranquilizer Increasingly Found in Illicit Fentanyl Samples. JAMA 2023; 329:1904.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhu DT, Friedman J, Bourgois P, et al. The emerging fentanyl-xylazine syndemic in the USA: challenges and future directions. Lancet 2023; 402:1949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deutsch SA, De Jong AR. Xylazine Complicating Opioid Ingestions in Young Children. Pediatrics 2023; 151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frisk-Holmberg M, Paalzow L, Edlund PO. Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy. Br J Clin Pharmacol 1981; 12:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dollery CT, Davies DS, Draffan GH, et al. Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 1976; 19:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowenthal DT. Pharmacokinetics of clonidine. J Cardiovasc Pharmacol 1980; 2 Suppl 1:S29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther 1985; 38:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowry JA, Garg U. Serum concentrations in three children with unintentional tetrahydrozoline overdose. Clin Toxicol (Phila) 2011; 49:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Toce MS, Freiman E, O'Donnell KA, Burns MM. Clinical Effects of Pediatric Clonidine Exposure: A Retrospective Cohort Study at a Single Tertiary Care Center. J Emerg Med 2021; 60:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterhoudt KC. No sympathy for a boy with obtundation. Pediatr Emerg Care 2004; 20:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wiley JF 2nd, Wiley CC, Torrey SB, Henretig FM. Clonidine poisoning in young children. J Pediatr 1990; 116:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiller HA, Klein-Schwartz W, Colvin JM, et al. Toxic clonidine ingestion in children. J Pediatr 2005; 146:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rapko DA, Rastegar DA. Intentional clonidine patch ingestion by 3 adults in a detoxification unit. Arch Intern Med 2003; 163:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Killian CA, Roberge RJ, Krenzelok EP, Stonage CL. "Cloniderm" toxicity: another manifestation of clonidine overdose. Pediatr Emerg Care 1997; 13:340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols MH, King WD, James LP. Clonidine poisoning in Jefferson County, Alabama. Ann Emerg Med 1997; 29:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isbister GK, Heppell SP, Page CB, Ryan NM. Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity. Clin Toxicol (Phila) 2017; 55:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams PL, Krafcik JM, Potter BB, et al. Cardiac toxicity of clonidine. Chest 1977; 72:784.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osterhoudt KC, Henretig FM. Sinoatrial node arrest following tetrahydrozoline ingestion. J Emerg Med 2004; 27:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaddar N, Vigneault P, Pilote S, et al. Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr. J Cardiovasc Pharmacol Ther 2012; 17:102.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minns AB, Clark RF, Schneir A. Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension. Clin Toxicol (Phila) 2010; 48:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hunyor SN, Bradstock K, Somerville PJ, Lucas N. Clonidine overdose. Br Med J 1975; 4:23.
          </a>
         </li>
         <li class="breakAll">
          Wiley JF. Clonidine and related imidazoline derivatives. In: Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, 4th ed, Shannon MW, Burns MJ (Eds), Saunders Elsevier, Philadelphia 2007. p.1001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fein DM, Hafeez ZF, Cavagnaro C. An overdose of extended-release guanfacine. Pediatr Emerg Care 2013; 29:929.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball NS, Knable BM, Relich TA, et al. Xylazine poisoning: a systematic review. Clin Toxicol (Phila) 2022; 60:892.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Malayala SV, Papudesi BN, Bobb R, Wimbush A. Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA. Cureus 2022; 14:e28160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rose L, Kirven R, Tyler K, et al. Xylazine-induced acute skin necrosis in two patients who inject fentanyl. JAAD Case Rep 2023; 36:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei J, Wachuku C, Berk-Krauss J, et al. Severe cutaneous ulcerations secondary to xylazine (tranq): A case series. JAAD Case Rep 2023; 36:89.
          </a>
         </li>
         <li class="breakAll">
          BTNX Inc. https://www.lochnessmedical.com/harmreduction/XYL_IFU.pdf (Accessed on June 16, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gremse DA, Artman M, Boerth RC. Hypertension associated with naloxone treatment for clonidine poisoning. J Pediatr 1986; 108:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmad SA, Scolnik D, Snehal V, Glatstein M. Use of naloxone for clonidine intoxication in the pediatric age group: case report and review of the literature. Am J Ther 2015; 22:e14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappagoda C, Schell DN, Hanson RM, Hutchins P. Clonidine overdose in childhood: implications of increased prescribing. J Paediatr Child Health 1998; 34:508.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsze DS, Dayan PS. Treatment of guanfacine toxicity with naloxone. Pediatr Emerg Care 2012; 28:1060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katar S, Taskesen M, Okur N. Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication. Pediatr Int 2010; 52:488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes JF, Berman DA. Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child. Pediatr Emerg Care 1999; 15:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge RJ, McGuire SP, Krenzelok EP. Yohimbine as an antidote for clonidine overdose. Am J Emerg Med 1996; 14:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schieber RA, Kaufman ND. Use of tolazoline in massive clonidine poisoning. Am J Dis Child 1981; 135:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsson JM, Pruitt AW. Management of clonidine ingestion in children. J Pediatr 1983; 103:646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shannon M, Neuman MI. Yohimbine. Pediatr Emerg Care 2000; 16:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chyka PA, Seger D. Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists. J Toxicol Clin Toxicol 1997; 35:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Juurlink DN. Activated charcoal for acute overdose: a reappraisal. Br J Clin Pharmacol 2016; 81:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horowitz R, Mazor SS, Aks SE, Leikin JB. Accidental clonidine patch ingestion in a child. Am J Ther 2005; 12:272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walton J, Byrum M, Shumaker A, Coury DL. Prolonged bradycardia and hypotension following guanfacine extended release overdose. J Child Adolesc Psychopharmacol 2014; 24:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta R, Holtgrave DR, Ashburn MA. Xylazine - Medical and Public Health Imperatives. N Engl J Med 2023; 388:2209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spadaro A, Connor KO, Lakamana S, et al. Self-reported Xylazine Experiences: A Mixed Methods Study of Reddit Subscribers. medRxiv 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrman-Dupre R, Kaigh C, Salzman M, et al. Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report. J Addict Med 2022; 16:595.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6509 Version 41.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6101302" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Drugs five years later: clonidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24094880" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929375" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trends and toxic effects from pediatric clonidine exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646419" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Poisonings Associated with Intubation: US National Poison Data System Exposures 2000-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29544366" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Naloxone reversal of clonidine toxicity: dose, dose, dose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30425077" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Clonidine exposures in children under 6 (2004-2017): a retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25225137" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Emergency hospitalizations for unsupervised prescription medication ingestions by young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33305966" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : 2019 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 37th Annual Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31008653" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pediatric guanfacine exposures reported to the National Poison Data System, 2000-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709054" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Heroin: what's in the mix?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17709054" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Heroin: what's in the mix?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37812779" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33536231" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Increasing presence of xylazine in heroin and/or fentanyl deaths, Philadelphia, Pennsylvania, 2010-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35247724" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Xylazine spreads across the US: A growing component of the increasingly synthetic and polysubstance overdose crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11818763" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Efficacy of clonidine for prevention of perioperative myocardial ischemia: a critical appraisal and meta-analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6103408" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Rapid opiate detoxification with clonidine and naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16207098" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Experience with an adult alcohol withdrawal syndrome practice guideline in internal medicine patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3367452" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Menopausal flushing: double-blind trial of a non-hormonal medication
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28526145" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Alpha-2 Agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10596256" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/89558" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clonidine in Tourette's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12874489" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16708135" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Pediatric prescribing practices for clonidine and other pharmacologic agents for children with sleep disturbance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7559307" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Guanfacine treatment of comorbid attention-deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18347496" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Central alpha-2 adrenergic eye drops: case series of 3 pediatric systemic poisonings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15462150" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Retrospective review of Tizanidine (Zanaflex) overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19124581" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Brimonidine tartrate poisoning in children: frequency, trends, and use of naloxone as an antidote.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33626597" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Adverse effects of brimonidine eye drop in children: A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33403870" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : High dose naloxone for acute tizanidine overdose in the emergency department: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14585459" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Are one or two dangerous? Clonidine and topical imidazolines exposure in toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32389431" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Clonidine Compounding Error: Bradycardia and Sedation in a Pediatric Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11483818" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6112622" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clonidine in thousand-fold overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24760708" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Unintentional pediatric ophthalmic tetrahydrozoline ingestion: case files of the medical toxicology fellowship at the University of California, San Francisco.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12126186" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Clonidine toxicity revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9851554" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Recent advances in imidazoline receptor research: ligands--localization and isolation--signaling--functional and clinical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11004028" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The effects of clonidine on human digital vasculature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24666288" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Significance of the imidazoline receptors in toxicology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11753193" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Severe intoxication from xylazine inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34698775" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Assessing a Veterinary Sedative's Role in Drug Overdose Deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35830662" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Xylazine and Overdoses: Trends, Concerns, and Recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35770859" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35770859" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33031124" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Xylazine, a Veterinary Tranquilizer, Detected in 42 Accidental Fentanyl Intoxication Deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37014353" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Opioid overdoses involving xylazine in emergency department patients: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37223922" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Here's What to Know About Xylazine, aka Tranq, the Animal Tranquilizer Increasingly Found in Illicit Fentanyl Samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37634523" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : The emerging fentanyl-xylazine syndemic in the USA: challenges and future directions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36550066" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Xylazine Complicating Opioid Ingestions in Young Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7332729" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1245090" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Clinical pharmacology and pharmacokinetics of clonidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6154834" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Pharmacokinetics of clonidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4028622" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pharmacokinetics of transdermally delivered clonidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21740144" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Serum concentrations in three children with unintentional tetrahydrozoline overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33036823" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Clinical Effects of Pediatric Clonidine Exposure: A Retrospective Cohort Study at a Single Tertiary Care Center.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15179152" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : No sympathy for a boy with obtundation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1969468" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clonidine poisoning in young children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15689921" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Toxic clonidine ingestion in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12578519" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Intentional clonidine patch ingestion by 3 adults in a detoxification unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9368249" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : "Cloniderm" toxicity: another manifestation of clonidine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9095013" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Clonidine poisoning in Jefferson County, Alabama.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28107093" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Adult clonidine overdose: prolonged bradycardia and central nervous system depression, but not severe toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/923317" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Cardiac toxicity of clonidine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15388224" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Sinoatrial node arrest following tetrahydrozoline ingestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21317414" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Tizanidine (Zanaflex): a muscle relaxant that may prolong the QT interval by blocking IKr.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20136479" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Guanfacine overdose resulting in initial hypertension and subsequent delayed, persistent orthostatic hypotension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1174908" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clonidine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1174908" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Clonidine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23925253" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : An overdose of extended-release guanfacine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35442125" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Xylazine poisoning: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36148197" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Philadelphia, Pennsylvania, USA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37288443" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Xylazine-induced acute skin necrosis in two patients who inject fentanyl.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37274146" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Severe cutaneous ulcerations secondary to xylazine (tranq): A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37274146" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Severe cutaneous ulcerations secondary to xylazine (tranq): A case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3701527" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Hypertension associated with naloxone treatment for clonidine poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23782760" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Use of naloxone for clonidine intoxication in the pediatric age group: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9928640" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clonidine overdose in childhood: implications of increased prescribing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23034493" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Treatment of guanfacine toxicity with naloxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20723124" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Naloxone use in a newborn with apnea due to tetrahydrozoline intoxication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10389957" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Use of naloxone to reverse symptomatic tetrahydrozoline overdose in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8906769" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Yohimbine as an antidote for clonidine overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7457448" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Use of tolazoline in massive clonidine poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6137526" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Management of clonidine ingestion in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10698146" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Yohimbine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9482427" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Position statement: single-dose activated charcoal. American Academy of Clinical Toxicology; European Association of Poisons Centres and Clinical Toxicologists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26409027" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Activated charcoal for acute overdose: a reappraisal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15891273" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Accidental clonidine patch ingestion in a child.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25010857" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Prolonged bradycardia and hypotension following guanfacine extended release overdose.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37099338" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Xylazine - Medical and Public Health Imperatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36993695" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Self-reported Xylazine Experiences: A Mixed Methods Study of Reddit Subscribers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35020700" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
